CI-1040

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCI-1040
Drug Alias NameCI-1040PD-184352
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncUniversity Of Alabama At Birmingham
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsPancreatic Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A